这家罕见病药企终止在华业务

Core Viewpoint - Ruikangdi (Beijing) Pharmaceutical Co., Ltd. has officially entered the liquidation process as of December 11, 2025, and will cease all business activities, impacting its ability to provide products and services for rare diseases in China [3][4]. Group 1: Company Overview - Ruikangdi was established in Beijing in 2021 as a subsidiary of the Italian pharmaceutical group Recordati, focusing on introducing rare disease medications to benefit Chinese patients [3]. - The company has received approval for three rare disease drugs in China, including treatments for methylmalonic acidemia, isovaleric acidemia, propionic acidemia, and hyperammonemia due to N-acetylglutamate synthase deficiency, as well as drugs for Cushing's syndrome and acromegaly [3]. Group 2: Market Impact - The sudden termination of Ruikangdi's operations raises concerns about the future availability of the approved rare disease medications in China [4]. - Among the approved drugs, there are currently no domestic generic versions available for the two key medications, indicating a potential gap in treatment options for patients [8]. Group 3: Industry Challenges - The rare disease pharmaceutical sector faces significant commercialization challenges, including low awareness, difficult diagnoses, and insufficient insurance coverage [8]. - The general public and healthcare professionals in China have limited knowledge about rare diseases, necessitating substantial investment in medical education and market development, which is both time-consuming and costly [9]. - Economic constraints for families of rare disease patients, particularly since approximately 80% of rare diseases are genetic and many patients are children, further complicate the affordability of treatments [9].